Аннотация:
Daytime sleepiness is one of the clinically significant non-motor manifestations of Parkinson's disease (PD). One of its insufficiently studied aspects is a relationship between daytime sleepiness and nighttime sleep disorders. Objective: to clarify the clinical characteristics of PD in patients with different types of daytime sleepiness and to estimate of the ratio of daytime sleepiness to clinical and polysomnographic characteristics of nighttime sleep in patients with advanced stages of PD. Patients and methods: The investigation included 110 patients (56 men and 54 women) (mean age, 63.78±0.6 years) with PD (Hoehn and Yahr stage 2.6±0.2; disease duration, 6.3±3.2 years) without dementia. All the patients received therapy with levodopa at a mean daily dose of 667.8 mg; 98 of them had the drug in combination with dopamine receptor agonists at a stable dose. The unified PD rating scale, the PD sleep scale (PDSS), and the Epworth sleepiness scale (ESS) were applied. Nocturnal polysomno
Нодель М. Р. Марина Романовна 1971-
Шевцова К. В.
Ковров Г. В. Геннадий Васильевич 1964-
Яхно Н. Н. Николай Николаевич 1944-
Nodel` M. R. Marina Romanovna 1971-
Shevtsova K. V.
Kovrov G. V. Gennadij Vasilyevich 1964-
Yakhno N. N. Nikolay Nikolaevich 1944-
Nighttime sleep disorders in patients with daytime sleepiness in Parkinson's disease
Текст визуальный непосредственный
Неврология, нейропсихиатрия, психосоматика
ИМА-Пресс
Т. 10, Вып. 4 С. 23-29
2018
Статья
Excessive daytime sleepiness Insomnia Multiple sleep latency test Parkinson's disease Polysomnography Rapid eye movement sleep behavior disorder
Daytime sleepiness is one of the clinically significant non-motor manifestations of Parkinson's disease (PD). One of its insufficiently studied aspects is a relationship between daytime sleepiness and nighttime sleep disorders. Objective: to clarify the clinical characteristics of PD in patients with different types of daytime sleepiness and to estimate of the ratio of daytime sleepiness to clinical and polysomnographic characteristics of nighttime sleep in patients with advanced stages of PD. Patients and methods: The investigation included 110 patients (56 men and 54 women) (mean age, 63.78±0.6 years) with PD (Hoehn and Yahr stage 2.6±0.2; disease duration, 6.3±3.2 years) without dementia. All the patients received therapy with levodopa at a mean daily dose of 667.8 mg; 98 of them had the drug in combination with dopamine receptor agonists at a stable dose. The unified PD rating scale, the PD sleep scale (PDSS), and the Epworth sleepiness scale (ESS) were applied. Nocturnal polysomno